A meta-analysis spanning the three cohorts reinforced these findings, indicating a unified HR of 1.72 (95% CI, 1.30–2.29) and negligible heterogeneity (I2 = 21.8%), thus firmly establishing high SLC3A2 expression as a harbinger of poor glioma prognosis (Fig. 10E). The gene discussed is SLC3A2; the disease is central nervous system cancer.